Current Phase III clinical trial results indicate that IL-1 blockade therapy significantly reduces ACPA and RF levels in patients’ serum and is positively correlated with the normalization of B-cell subset ratios, suggesting that targeting the IL-1 family may be a strategy for regulating abnormal B-cell activation and improving the course of RA (Winkler et al., 2021). Here, IL1A is linked to rheumatoid arthritis.